Stantech Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 75.01 K
as on 16-11-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.61 Cr
as on 16-11-2024
- Revenue 65.77%
(FY 2023)
- Profit -306.98%
(FY 2023)
- Ebitda 90.65%
(FY 2023)
- Net Worth -22.27%
(FY 2023)
- Total Assets 14.11%
(FY 2023)
About Stantech Pharmaceuticals
The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 75.01 K .
The company currently has active open charges totaling ₹8.61 Cr.
Pankaj Yambal, Rohit Yambal, and Swati Jain serve as directors at the Company.
- CIN/LLPIN
U24230MH2005PTC153516
- Company No.
153516
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Stantech Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Yambal  | Director | 01-Apr-2019 | Current |
| Rohit Yambal | Director | 01-Apr-2019 | Current |
| Swati Jain | Additional Director | 18-Dec-2021 | Current |
Financial Performance and Corporate Structure Insights of Stantech Pharmaceuticals.
Stantech Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 65.77% increase. The company also saw a substantial fall in profitability, with a 306.98% decrease in profit. The company's net worth observed a substantial decline by a decrease of 22.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stantech Pharmaceuticals?
In 2023, Stantech Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sydler Technologies Private LimitedActive 11 years 1 monthPankaj Yambal and Rohit Yambal are mutual person
Sydler Remedies Private LimitedActive 21 years 4 monthsPankaj Yambal and Rohit Yambal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Apr 2021 | ₹8.61 Cr | Open |
How Many Employees Work at Stantech Pharmaceuticals?
Stantech Pharmaceuticals has a workforce of 24 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stantech Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stantech Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
